MDB Capital Holdings LLC Dossier - Source-backed chat

MDB Capital Holdings LLC

MDBHNASDAQ

SectorFinancials

IndustryInvestment Banking & Brokerage

Beta (adjusted)1.14

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $2.44Price as of 1 Oct 2026

Data confidence Sign in to view data confidence

Market Cap $25.5M

Enterprise Value $15.9M

Shares Outstanding 10.4M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

MDB Capital Holdings, LLC operates a unique public venture capital model designed to launch, fund, and commercialize early-stage, disruptive technology and life sciences companies. While the firm possesses high-potential assets—including a significant equity stake in eXoZymes (EXOZ), a fully funded seed position in Paulex Bio, and proprietary platforms like PatentVest and MDB Direct—it remains in a heavy investment phase. The company's financial performance is currently characterized by negative operating income and substantial net losses due to high overhead and strategic development costs. A 'Hold' recommendation is warranted as the market awaits the execution of planned spin-offs, which are expected to reduce annual operating expenses to $6 million, and the commercialization/IPO milestones of its partner companies.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$2.4515%

The bear case materializes if the micro-cap public markets remain highly contracted and illiquid, preventing successful IPOs for pipeline companies like Buda Juice and Paulex Bio. Furthermore, if eXoZymes (EXOZ) faces severe going-concern issues or dilutes its equity heavily, MDB's asset base will erode. Delays in spinning off PatentVest and MDB Direct would prolong the high $10 million annual cash burn, forcing MDB to seek dilutive financing.

Base CaseCentral scenario

$3.5060%

The base case assumes MDB continues to make steady progress on its pipeline but experiences typical micro-cap execution delays. Operating expenses decline gradually as spin-offs are finalized, and cash burn is managed within acceptable limits using the firm's $22.3 million in net current assets. Paulex Bio initiates clinical trials but its IPO timeline may stretch into late 2026 or early 2027. The stock continues to trade near its book value, reflecting its low float and lack of institutional analyst coverage.

Bull CaseUpside scenario

$5.5025%

The bull case is driven by the successful execution of strategic spin-offs for PatentVest (as an AI-enhanced IP law firm) and MDB Direct, which dramatically lowers MDB's fixed cost structure. Simultaneously, the successful September 2026 IPO of Paulex Bio at a multi-billion-dollar implied valuation, combined with a recovery in eXoZymes' (EXOZ) share price, unlocks massive balance sheet value. Underwriting and advisory fees from Public Ventures scale rapidly as the firm increases its launch cadence to 3-5 companies per year.

Scenarios reflect our research view at the research date.

Key Investment Merits

Unique public venture model providing retail investors with early-stage venture access and public market liquidity.
Substantial asset backing, including a ~47% stake in eXoZymes (valued at ~$30M in early 2026) and 7.1M shares/warrants in Paulex Bio.
Proprietary IP intelligence platform (PatentVest) leveraging a 20-year database and agentic AI to dominate patent strategy.
Strong balance sheet with $22.3 million in cash, current assets, and marketable securities (less liabilities) at year-end 2025.

Key Investment Risks

High operating cash burn and negative operating income during the pre-revenue/early-commercialization phase of partner companies.
Extreme illiquidity and low float of MDBH shares, leading to high price volatility and lack of institutional analyst coverage.
Dependence on highly volatile micro-cap IPO markets for asset realization and fee generation.
Going-concern and funding risks at key portfolio holdings like eXoZymes.

Thesis Invalidation Triggers

Failure to complete the spin-offs of PatentVest and MDB Direct, leaving annual fixed operating expenses elevated at $10 million.
A severe write-down of the eXoZymes (EXOZ) investment or failure of Paulex Bio to initiate clinical trials.
Inability of Public Ventures to underwrite or close planned offerings (e.g., Buda Juice IPO or Paulex Bio private placements).

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.